Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Hepatitis B and C in sexual health

Essential points for quick revision.

Saved on this device
!
Hepatitis with failing liver function

Confusion, drowsiness, asterixis, hypoglycaemia, spontaneous bleeding, a rising INR, acidosis or renal deterioration indicates possible acute liver failure rather than a routine positive-virus referral.

Action: Use ABCDE, check glucose and coagulation urgently, treat hypoglycaemia, stop potential hepatotoxins and discuss immediately with critical care, hepatology and the transplant service. Send virus-directed tests, including HBV and HDV assessment when relevant, without delaying organ support.

Synopsis

Use a sexual-health visit to interpret HBV and HCV results accurately, act on recent exposure, prevent hepatitis B, identify current hepatitis C viraemia, and secure named linkage for liver assessment and treatment.

  • HBV spreads efficiently through sexual and blood exposure; HCV is chiefly blood-borne, with sexual transmission concentrated where blood, mucosal trauma, injecting, HIV or ulcerative STI is present.
  • Read HBV as a three-marker pattern: HBsAg indicates current infection, anti-HBc records natural exposure and anti-HBs indicates immunity; vaccination produces anti-HBs without anti-HBc.
  • A reactive anti-HCV result records exposure, not current infection; reflex HCV RNA or a validated core-antigen route establishes active viraemia.

Key red flags

Jaundice with confusion, asterixis, bleeding, hypoglycaemia or deteriorating coagulation requires emergency liver-failure care.

HBsAg positivity in pregnancy needs prompt HBV DNA assessment and a documented plan for maternal care and neonatal immunoprophylaxis.

An infant born to an HBsAg-positive mother must receive hepatitis B vaccine within 24 hours and HBIG when the current national criteria apply.

Chemotherapy, major immunosuppression or B-cell-depleting treatment must not begin before HBsAg and anti-HBc results have been reviewed and reactivation prevention assigned.

A sudden ALT rise or jaundice in chronic HBV requires assessment for disease activity, reactivation, adherence, drug injury and hepatitis D.

A recent sexual, injecting, occupational or household blood exposure needs same-day assessment because hepatitis B vaccine and selected HBIG are time sensitive.

Established chronic liver disease

Thrombocytopenia, splenomegaly, spider naevi, ascites or abnormal synthetic function may reveal advanced HBV or HCV even after years of few symptoms.

Acute liver failure

Encephalopathy, coagulopathy, hypoglycaemia, bleeding or rapid multiorgan deterioration requires emergency liver and transplant-centre involvement.

Investigation priorities

01
HBsAg, total anti-HBc and anti-HBs panelFirst step

Assign the patient to current HBV infection, resolved natural infection, vaccine immunity or susceptibility.

Management branches

RESULTSTurn screening markers into two diagnoses

The laboratory reports HBsAg positivity and reactive anti-HCV in the same asymptomatic patient.

  1. Complete the HBV marker panel, arrange HBV DNA and liver or fibrosis assessment, and refer current HBV through the named pathway.
  2. Reflex the anti-HCV sample to RNA because antibody cannot distinguish current infection from previous clearance or cure.

Key medicines

Specialist-selected chronic hepatitis B antiviralHBsAg-positive adults need hepatology assessment and dose selection under the dedicated HBV treatment guideline; sexual-health assessment alone does not determine a universal regimen.Choice and duration depend on compensated or decompensated disease, renal and bone function, pregnancy, previous antiviral exposure or resistance and HIV coinfection. HIV coinfection needs a fully suppressive ART combination with adequate HBV activity.
Specialist-selected hepatitis C direct-acting antiviral regimenDetectable HCV RNA requires specialist selection of the combination and duration under the dedicated HCV treatment guideline.Regimen and duration depend on liver compensation, previous treatment or failure, renal function, pregnancy, HBV or HIV coinfection and medicine interactions; use the current dedicated HCV treatment body.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom